Streamline Your B Cell Research from Isolation to Expansion
Due to their essential role in the adaptive immune response, B cells continue to be a focal point for infectious disease, cancer, and autoimmune research. Isolating and generating these cells in relevant numbers continues to be a major challenge in the field. Join this on-demand webinar to learn about reagents for efficient B cell isolation and expansion. This workshop features streamlined culture systems that enable feeder- and serum-free expansion of both human and mouse B cells with high yields, thus providing a complete workflow solution for B cell research.
Therapeutic Application of Endothelial Colony-Forming Cells for Retinal Diseases
In this webinar, Drs. Susumu Sakimoto and Valentina Marchetti discuss their current research on generating human endothelial colony-forming cells (ECFCs) under xeno-free conditions to treat vascular abnormalities in the eye. Vascular abnormalities are a common component of eye diseases that often lead to vision loss. It is possible to use one cell type to rescue another cell type in the face of severe stress. Dr. Susumu will present his study on how human ECFCs injected into the vitreous cavity rescue vaso-obliteration and neurodegeneration in animal models of retinal disease. These results help us understand the mechanism of ECFC-based therapies for ischemic insults and retinal neurodegenerative diseases. Dr. Valentina Marchetti will present a workflow to derive and expand ECFCs under xeno-free conditions using the EC-Cult™-XF ECFC Culture Kit.
Re-Creating Disease with Kidney Organoids and CRISPR
In this webinar, Dr. Benjamin Freedman from the University of Washington provides an overview of re-creating disease using kidney organoids and CRISPR-Cas9 genome editing. As a postdoctoral fellow in the Renal Division at Brigham and Women’s Hospital at Harvard Medical School, Dr. Freedman was responsible for several innovative techniques that he describes in this webinar, including differentiation of human pluripotent stem cells (hPSCs) into kidney organoids containing nephron-like segments and generating knockout mutations in organoids with CRISPR.
Studying Cystic Fibrosis Using Primary Human Nasal Epithelial Cells
Cystic Fibrosis (CF) is a genetic disease that affects multiple organs in the body. The primary defects are in the airway and related to epithelial dysfunction. Technological advances have enabled researchers to study CF using specialized in vitro cell culture models to recapitulate the pseudostratified airway epithelium. In this webinar, Dr. Theo Moraes elaborates on the advantages of using nasal epithelial cell cultures to perform such studies and their implications for precision medicine in CF. He also discusses the Program for Individualized Cystic Fibrosis Therapy (CFIT)—a collaboration between CF Canada, SickKids Foundation, and The Hospital for Sick Children—and how it utilizes the nasal culture methodology to develop a nationally accessible resource and to accelerate the development of individualized therapies for CF patients.
Dr. Theo Moraes is a clinician and researcher at The Hospital for Sick Children and the SickKids Research Institute in Toronto, Canada.
EasySep™小鼠TIL（CD45）正选试剂盒
Why Use Semi-Solid Medium for Cloning Hybridomas and CHO Cells Cloning hybridomas and CHO cells can be done faster and more efficiently using semi-solid cloning, compared to traditional cloning techniques
Streamline Your B Cell Research from Isolation to Expansion Due to their essential role in the adaptive immune response, B cells continue to be a focal point for infectious disease, cancer, and autoimmune research. Isolating and generating these cells in relevant numbers continues to be a major challenge in the field. Join this on-demand webinar to learn about reagents for efficient B cell isolation and expansion. This workshop features streamlined culture systems that enable feeder- and serum-free expansion of both human and mouse B cells with high yields, thus providing a complete workflow solution for B cell research.
Therapeutic Application of Endothelial Colony-Forming Cells for Retinal Diseases In this webinar, Drs. Susumu Sakimoto and Valentina Marchetti discuss their current research on generating human endothelial colony-forming cells (ECFCs) under xeno-free conditions to treat vascular abnormalities in the eye. Vascular abnormalities are a common component of eye diseases that often lead to vision loss. It is possible to use one cell type to rescue another cell type in the face of severe stress. Dr. Susumu will present his study on how human ECFCs injected into the vitreous cavity rescue vaso-obliteration and neurodegeneration in animal models of retinal disease. These results help us understand the mechanism of ECFC-based therapies for ischemic insults and retinal neurodegenerative diseases. Dr. Valentina Marchetti will present a workflow to derive and expand ECFCs under xeno-free conditions using the EC-Cult™-XF ECFC Culture Kit.
Re-Creating Disease with Kidney Organoids and CRISPR In this webinar, Dr. Benjamin Freedman from the University of Washington provides an overview of re-creating disease using kidney organoids and CRISPR-Cas9 genome editing. As a postdoctoral fellow in the Renal Division at Brigham and Women’s Hospital at Harvard Medical School, Dr. Freedman was responsible for several innovative techniques that he describes in this webinar, including differentiation of human pluripotent stem cells (hPSCs) into kidney organoids containing nephron-like segments and generating knockout mutations in organoids with CRISPR.
Studying Cystic Fibrosis Using Primary Human Nasal Epithelial Cells Cystic Fibrosis (CF) is a genetic disease that affects multiple organs in the body. The primary defects are in the airway and related to epithelial dysfunction. Technological advances have enabled researchers to study CF using specialized in vitro cell culture models to recapitulate the pseudostratified airway epithelium. In this webinar, Dr. Theo Moraes elaborates on the advantages of using nasal epithelial cell cultures to perform such studies and their implications for precision medicine in CF. He also discusses the Program for Individualized Cystic Fibrosis Therapy (CFIT)—a collaboration between CF Canada, SickKids Foundation, and The Hospital for Sick Children—and how it utilizes the nasal culture methodology to develop a nationally accessible resource and to accelerate the development of individualized therapies for CF patients.
